Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients
Nephrology Dialysis Transplantation · 2024
DOI: 10.1093/ndt/gfad248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Hirohito Goto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Cardiovascular Diseases, Fibric Acids, Hypolipidemic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The high risk of major adverse cardiovascular events (MACE) in patients with chronic kidney disease (CKD) has been well described. However, the efficacy of fibrates on the risk of MACE in patients with CKD remains unclear.
Methods
We conducted a nested case–control study using data from a large administrative database that included more than 1.5 million Japanese patients. We defined cases as CKD patients with incidences of MACE and matched them with controls based on age, sex, calendar year of cohort entry and CKD stage. Fibrate exposure timing was categorized as current, recent or past. A conditional logistic regression analysis was used to investigate the association between fibrate use and the risk of MACE.
Results
Our study included 47 490 patients with CKD, with 15 830 MACE identified during a median follow-up of 9.4 months. The numbers of fibrates used during the study period were 556 (3.5%) in the case group and 1109 (3.5%) in the control group. Fibrate use was significantly associated with a decreased risk of MACE [odds ratio (OR) 0.84; 95% confidence interval (CI) 0.75–0.94], particularly for current (OR 0.81; 95% CI 0.68–0.97) and recent use (OR 0.65; 95% CI 0.48–0.90). Regarding the class effect of fibrates, pemafibrate use, but not bezafibrate or fenofibrate use, was significantly associated with a decreased risk of MACE (OR 0.73; 95% CI 0.528–0.997).
Conclusion
Recent and current fibrate use, especially pemafibrate use, was associated with a reduced risk of MACE in patients with CKD. This suggests the potential benefits of continuous fibrate therapy and the possible superiority of pemafibrate over other fibrates. However, further investigations in different populations are required to confirm the generalizability of these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University Hospital, Kanagawa, Japan.
- Department of Clinical Pharmacy, Division of Clinical Research and Development, School of Pharmacy, Showa University, Tokyo, Japan.
ORCID-Profile: Ken Iseri
Zitieren
APA
Goto, H., Iseri, K., & Hida, N. (2024). Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfad248
Vancouver
Goto H, Iseri K, Hida N. Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfad248
BibTeX
@article{Goto2024,
author = {Goto, Hirohito and Iseri, Ken and Hida, Noriko},
title = {Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
doi = {10.1093/ndt/gfad248}
}
EUVIMED